Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017 Dec 01; 123(23):4653-4662.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
Dermatologic Agents
Double-Blind Method
Female
Follow-Up Studies
Head and Neck Neoplasms
Humans
Isotretinoin
Male
Middle Aged
Neoplasm Staging
Neoplasms, Second Primary
Prognosis
United States

authors with profiles

Janardan Khandekar